Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 6/20 | 0.37 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL636818 | 0.90 | SMN1; SMN2 (0.37) | SMN1; SMN2GAAHPGDUTS2RWDR91 | |
| SCHEMBL637530 | 0.84 | SMN1; SMN2 (0.36) | SMN1; SMN2GAAHPGDUTS2RWDR91 | |
| SCHEMBL636378 | 0.83 | HPGD (0.37) | SMN1; SMN2GAAHPGDUTS2RWDR91 | |
| SCHEMBL27636974 | 0.80 | UTS2R (0.47) | UTS2R | |
| SCHEMBL916225 | 0.78 | ATM (0.42) | SMN1; SMN2GAAHPGDLMNA | |
| SCHEMBL640477 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2GAAHPGDUTS2RWDR91 | |
| SCHEMBL636488 | 0.77 | SMN1; SMN2 (0.39) | SMN1; SMN2GAAHPGDUTS2RWDR91 | |
| SCHEMBL636833 | 0.76 | SMN1; SMN2 (0.40) | SMN1; SMN2GAAHPGDUTS2RWDR91 | |
| SCHEMBL639638 | 0.75 | CACNA1B (0.40) | SMN1; SMN2GAAHPGDUTS2RCCR1 | |
| SCHEMBL636817 | 0.75 | SMN1; SMN2 (0.35) | SMN1; SMN2GAAHPGDLMNACCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021571-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20090234138-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS | XENOPORT, INC. | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234138-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS | APEH, ABAT, GABARAPL1 | SMN1; SMN2 377/4885GAA 98/4885HPGD 1031/4885 |
| US-20110021571-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | SMN1; SMN2 594/4885GAA 148/4885HPGD 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.